Adalimumab/etanerceptLatent tuberculosis infection: 7 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2013年 / 1444卷 / 1期

关键词：

D O I：

10.1007/s40278-013-2024-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：6 / 6

相关论文

共 50 条

[21] Adalimumab/etanercept/infliximabMalignancy: 7 case reports
Reactions Weekly, 2015, 1565 (1) : 19 - 19
[22] Adalimumab/tocilizumabLack of efficacy: 7 case reports
Reactions Weekly, 2023, 1967 (1) : 23 - 23
[23] Adalimumab/infliximabVarious toxicities: 7 case reports
Reactions Weekly, 2018, 1707 (1) : 19 - 19
[24] Adalimumab/etanercept/infliximabBronchospasm: 7 case reports
Reactions Weekly, 2009, 1272 (1) : 5 - 6
[25] Adalimumab/etanerceptVarious toxicities: 7 case reports
Reactions Weekly, 2019, 1781 (1) : 18 - 18
[26] Adalimumab/infliximabAutoimmune hepatitis: 7 case reports
Reactions Weekly, 2018, 1732 (1) : 24 - 24
[27] Adalimumab/golimumab/infliximabMilliary tuberculosis and bronchial tuberculosis: 5 case reports
Reactions Weekly, 2021, 1842 (1) : 14 - 14
[28] Adalimumab/infliximab/ustekinumabMiliary tuberculosis and latent tuberculosis: 4 case reports
Reactions Weekly, 2020, 1797 (1) : 18 - 18
[29] Adalimumab/infliximab/ustekinumabSeroconversion of latent tuberculosis infection (LTBI) from negative to positive and pulmonary tuberculosis: 3 case reports
Reactions Weekly, 2021, 1847 (1) : 23 - 23
[30] Adalimumab/etanercept/infliximabPulmonary and gastrointestinal tuberculosis: 4 case reports
Reactions Weekly, 2015, 1554 (1) : 17 - 17

← 1 2 3 4 5 →